NextCure, Inc.

Analysis for Ticker: NXTC

NextCure Inc is a clinical stage biotechnology company that searches for new ways to treat cancer by studying how the immune system interacts with tumors. The business sounds like a miracle but the internal math is a disaster. They have never sold a single product or made a dollar of revenue yet they have already spent 436,0$ million of other people's money. It is like a person who buys a mansion with a credit card and starts selling the windows and doors to pay the interest while the roof is already on fire. The decay became impossible to ignore in 2023 when the company burned through 62,7$ million. By 03/2024 they were forced to fire 37,0% of their employees and shut down their own manufacturing labs just to keep the lights on. Even as they shrank the business lost another 55,6$ million in 2024. While regular investors saw the value of their shares evaporate the chief executive officer Michael Richman took 1,5$ million in pay that year. By 03/02/2025 the Nasdaq exchange warned them they would be kicked off because their stock was worth less than 1,00$ for thirty days straight.